Zepbound’s growth fuels new employer coverage models

INDIANAPOLIS — The success of Eli Lilly’s blockbuster weight-loss drug Zepbound (tirzepatide) is fueling a surge of new access strategies, as employers, pharmacies, and digital health platforms work to help patients afford the rapidly expanding obesity treatment.

At the core of this effort is Lilly’s newly launched Employer Connect platform, which enables employers to work with independent program administrators to provide access to obesity medications while ensuring greater pricing transparency and better cost control. Through the program, Zepbound’s multi-dose KwikPen device is available to network pharmacies at $449 per month for all doses, allowing employers to subsidize part of the cost and help lower employees’ out-of-pocket expenses.

Zepbound now available in multi-dose KwikPen

Used by millions of patients worldwide, the KwikPen for single-patient use offers a new option for receiving Zepbound.

Chain Drug ReviewThorvardur de Shong

The initiative aims to address one of the biggest barriers to obesity treatment in the United States: inconsistent insurance coverage. Lilly estimates that about half of commercially insured workers do not have access to obesity medications coverage despite high demand for GLP-1 therapies.

The Employer Connect platform launches with over 15 independent program administrators, including GoodRx, Teladoc Health, Sesame, 9amHealth, and Mark Cuban Cost Plus Drug Company. These partners provide services ranging from benefits administration to more comprehensive obesity management programs that may include telehealth visits, nutrition counseling, and behavioral support.

Meanwhile, GoodRx is expanding access to the Zepbound KwikPen for employers through its GoodRx Employer Direct platform. The program allows self-insured employers to subsidize Lilly’s $449 pricing while giving companies flexibility in how much they contribute to employees’ prescriptions.

GoodRx to expand employer-sponsored access to Zepbound KwikPen

GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs.

Chain Drug ReviewCDR

At the same time, Amazon Pharmacy has started offering the Zepbound KwikPen with transparent self-pay prices beginning at $299 per month for the 2.5 mg initial dose, allowing patients with a valid prescription to order the medication online and have it delivered directly to their homes.

“Convenient access to medications and clear, transparent pricing are at the heart of what we do at Amazon Pharmacy,” said Tanvi Patel, vice president and general manager of Amazon Pharmacy.

Amazon Pharmacy expands access to Eli Lilly’s Zepbound KwikPen for weight management

Now offering customers transparent cash-pay pricing starting at $299 per month for the 2.5 mg KwikPen starter dose and convenient, fast home delivery.

Chain Drug ReviewCDR

The KwikPen device, recently approved by the U.S. Food and Drug Administration, provides a full month of treatment in one device, offering an alternative to single-dose injections and making weekly administration easier.

Zepbound has quickly become one of the most widely prescribed injectable obesity medications in the United States. Clinical studies have shown that patients taking the drug achieved significant weight loss when combined with diet and exercise, including average reductions of more than 20% of body weight in trials.

The growing employer programs and pharmacy partnerships highlight the rapid expansion of the GLP-1 obesity treatment market, as pharmaceutical companies, employers, and healthcare providers seek new ways to increase access to high-demand weight-management therapies.